E-ISSN 2602-3164
EJMI. 2021; 5(1): 89-94 | DOI: 10.14744/ejmi.2020.39466

The Importance of Platinum Sensitivity in Metastatic Malignant Pleural Mesothelioma Patients

Birol Ocak1, Ahmet Bilgehan Sahin1, Bahar Dakiki2, Hikmet Ulu Odman2, Neslihan Hazel Saydam2, Sibel Oyucu Orhan1, Turgut Kacan3, Adem Deligonul1, Erdem Cubukcu1, Turkkan Evrensel1
1Departmant of Medical Oncology, Uludag University Faculty of Medicine, Bursa, Turkey, 2Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa, Turkey, 3Departmant of Medical Oncology, Bursa Yüksek Ihtisas Training and Research Hospital, Bursa, Turkey

Objectives: Malignant pleural mesothelioma (MPM) accounts for approximately 80% of all mesothelioma cases. Methods: Forty-three patients diagnosed with advanced MPM were included in our study. We aimed to investigate first-line therapy options and the importance of platinum sensitivity in patients diagnosed with MPM, who were de novo metastatic or progressed from the early to the metastatic stage. Results: The mean age of the patients was 58.8±11.7 years, and 58.1% (25 patients) were male. The median overall survival (OS) was found to be 10.5 months (CI 95% 5.8-15.2). Median progression-free survival (PFS) of all MPM patients was 7.6 months (CI 95% 6.2-7.9). When comparing the platinum-sensitive group to the platinum-resistant group, the median OS of the platinum-sensitive group was found to be 10.5 months (CI 95% 4.6-16.5), and the median OS of the platinum-resistant group was 3.3 months (CI 95% 3.1-3.6) (p=0.02). The median PFS of the platinumsensitive group was 7.9 months (CI 95% 5.9-9.9), while that for the platinum-resistant group was 2.4 months (CI 95% 2.1-2.8) (p<0.01). Conclusion: Platinum-based chemotherapy regimens should be considered first at the metastatic stage. Keywords: Chemotherapy, metastatic malignant pleural mesothelioma, platinum sensitivity


Cite This Article

Ocak B, Sahin A, Dakiki B, Odman H, Saydam N, Orhan S, Kacan T, Deligonul A, Cubukcu E, Evrensel T. The Importance of Platinum Sensitivity in Metastatic Malignant Pleural Mesothelioma Patients. EJMI. 2021; 5(1): 89-94

Corresponding Author: Birol Ocak

Full Text PDF PDF Download
EJMI & EJMI